Olympus Launches a Venture Fund

article image

As part of its effort to enhance its focus on innovation and clinical impact, scope giant Olympus has launched a new corporate venture fund, Olympus Innovation Ventures.

For Olympus Corp., formalizing Olympus Innovation Ventures (OIV), its new corporate venture fund, is a logical outgrowth of a more concerted strategy the company launched a couple of years ago to evolve from a low- or mid-tech scope company into one more deeply engaged in advancing the clinical or therapeutic impact of its technology. Townsend Goddard, global head of business development for Olympus, talks of what he calls Olympus’ transformation. “Our ambition is to be a leading global medtech company, and to get there, we felt it was important to be more creative about how we source innovation,” he says, an initiative that includes making more equity investments in promising medtech start-ups. And, he continues, “The best way to do that is to professionalize that activity, be more systematic about it, and have a commitment from Olympus to the venture community,” all part of what he calls “a continuum of tools that we use in business development.”


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: